8-K Announcements
6Material company update
Apr 14, 2026·SEC
Material company update
Jan 21, 2026·SEC
Material company update
Oct 14, 2025·SEC
Johnson & Johnson(JNJ)Earnings, Financials & Key Ratios
JNJ•NYSE
39.4× P/E·Price updated Jun 19, 2026
AboutJohnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.Show more
- Revenue$88.82B+4.3%
- EBITDA$29.49B-4.6%
- Net Income$14.07B-60.0%
- EPS (Diluted)5.79-57.8%
- Gross Margin69.07%+0.4%
- EBITDA Margin33.2%-8.5%
- Operating Margin24.94%-9.3%
- Net Margin15.84%-61.6%
- ROE20.06%-58.5%
JNJ Key Insights
Johnson & Johnson (JNJ) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Dividend Aristocrat: 56 years of consecutive increases
- ✓Excellent 3Y average ROE of 30.7%
- ✓FCF machine: 22.3% free cash flow margin
- ✓High quality earnings: Operating CF exceeds net income
- ✓Healthy dividend yield of 2.1%
- ✓Share count reduced 5.1% through buybacks
✗Weaknesses
No significant weaknesses identified
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when JNJ posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
JNJ Price & Volume
Johnson & Johnson (JNJ) stock price & volume — 10-year historical chart
Loading chart...
JNJ Growth Metrics
Johnson & Johnson (JNJ) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years1.8%
5 Years1.6%
3 Years4.1%
TTM3.75%
Profit CAGR
10 Years-1.48%
5 Years-1.43%
3 Years-12.33%
TTM78.58%
EPS CAGR
10 Years0.16%
5 Years0.56%
3 Years-9.49%
TTM78.93%
Return on Capital
10 Years16.91%
5 Years16.58%
3 Years17.27%
Last Year17.64%
JNJ Recent Earnings
Johnson & Johnson (JNJ) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 11/12 qtrs (92%)●Beat Revenue 10/12 qtrs (83%)
Q2 2026Latest
Apr 14, 2026Metric
Actual
Est
EPS
$2.70+0.7%
$2.68
Rev
$24.1B+1.9%
$23.6B
Q1 2026
Jan 21, 2026Metric
Actual
Est
EPS
$2.46+0.0%
$2.46
Rev
$24.6B+1.7%
$24.1B
Q4 2025
Oct 14, 2025Metric
Actual
Est
EPS
$2.80+1.4%
$2.76
Rev
$24.0B+1.0%
$23.8B
Q3 2025
Jul 16, 2025Metric
Actual
Est
EPS
$2.77+3.4%
$2.68
Rev
$23.7B+3.9%
$22.9B
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Apr 14, 2026 | $2.70vs $2.68+0.7% | $24.1Bvs $23.6B+1.9% |
| Q1 2026 | Jan 21, 2026 | $2.46vs $2.46+0.0% | $24.6Bvs $24.1B+1.7% |
| Q4 2025 | Oct 14, 2025 | $2.80vs $2.76+1.4% | $24.0Bvs $23.8B+1.0% |
| Q3 2025 | Jul 16, 2025 | $2.77vs $2.68+3.4% | $23.7Bvs $22.9B+3.9% |
Based on last 12 quarters of dataView full earnings history →
JNJ Peer Comparison
Johnson & Johnson (JNJ) competitors in Large diversified branded pharma — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 ABT | 153.68B | 88.38 | 11.57 | 4.59% | 31.88% | 27.26% | 0.32 | |
 PFE | 143.46B | 25.22 | 18.54 | -1.65% | 11.83% | 8.34% | 0.78 | |
 MRK | 281.25B | 113.87 | 15.64 | 1.18% | 28.12% | 36.14% | 0.96 | |
 LLY | 1.04T | 1098.13 | 47.85 | 44.7% | 34.98% | 101.17% | 1.60 | |
 BMY | 110.25B | 54.00 | 15.65 | -0.22% | 15.01% | 38.96% | 2.55 | |
 ABBV | 383.17B | 216.63 | 91.41 | 8.57% | 6.91% | 62.15% | ||
 NVS | 280.64B | 147.08 | 20.46 | 5.97% | 24.14% | 31.42% | 0.80 | |
 SYK | 117.88B | 307.80 | 36.64 | 11.16% | 12.92% | 15.04% | 0.66 |
Compare JNJ vs Peers
Johnson & Johnson (JNJ) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
JNJ Income Statement
Johnson & Johnson (JNJ) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 71.89B | 76.45B | 81.58B | 82.06B | 82.58B | 78.74B | 79.99B | 85.16B | 88.82B | 92.15B |
Revenue Growth % | 2.59% | 6.34% | 6.71% | 0.59% | 0.64% | -4.65% | 1.59% | 6.46% | 4.3% | 3.75% |
Cost of Goods Sold | 21.79B | 25.44B | 27.09B | 27.56B | 28.43B | 23.4B | 24.6B | 26.55B | 27.47B | 29.42B |
COGS % of Revenue | 30.31% | 33.28% | 33.21% | 33.58% | 34.42% | 29.72% | 30.75% | 31.18% | 30.93% | - |
Gross Profit | 50.1B▲ 0% | 51.01B▲ 1.8% | 54.49B▲ 6.8% | 54.5B▲ 0.0% | 54.16B▼ 0.6% | 55.34B▲ 2.2% | 55.39B▲ 0.1% | 58.61B▲ 5.8% | 61.35B▲ 4.7% | 62.73B▲ 0% |
Gross Margin % | 69.69% | 66.72% | 66.79% | 66.42% | 65.58% | 70.28% | 69.25% | 68.82% | 69.07% | 68.08% |
Gross Profit Growth % | 3.22% | 1.82% | 6.82% | 0.02% | -0.63% | 2.18% | 0.1% | 5.8% | 4.68% | - |
Operating Expenses | 29.21B | 32.11B | 33.31B | 33.53B | 34.42B | 34.4B | 34.38B | 35.2B | 39.2B | 38.69B |
OpEx % of Revenue | 40.63% | 42.01% | 40.84% | 40.86% | 41.68% | 43.68% | 42.98% | 41.33% | 44.13% | - |
Selling, General & Admin | 20.07B | 21.52B | 22.54B | 22.18B | 22.08B | 20.12B | 20.25B | 20.11B | 21.97B | 22.98B |
SG&A % of Revenue | 27.91% | 28.15% | 27.63% | 27.03% | 26.74% | 25.55% | 25.31% | 23.62% | 24.73% | - |
Research & Development | 9.14B | 10.59B | 10.78B | 11.36B | 12.34B | 14.28B | 14.13B | 15.09B | 17.23B | 15.71B |
R&D % of Revenue | 12.72% | 13.86% | 13.21% | 13.84% | 14.94% | 18.13% | 17.67% | 17.71% | 19.4% | - |
Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Operating Income | 20.89B▲ 0% | 18.9B▼ 9.5% | 21.18B▲ 12.1% | 20.97B▼ 1.0% | 19.73B▼ 5.9% | 20.94B▲ 6.1% | 21.01B▲ 0.3% | 23.41B▲ 11.4% | 22.15B▼ 5.4% | 24.05B▲ 0% |
Operating Margin % | 29.06% | 24.72% | 25.96% | 25.55% | 23.89% | 26.6% | 26.27% | 27.49% | 24.94% | 26.09% |
Operating Income Growth % | 14.23% | -9.54% | 12.05% | -0.97% | -5.9% | 6.13% | 0.33% | 11.4% | -5.38% | - |
EBITDA | 24.64B | 24.54B | 28.1B | 27.98B | 26.96B | 28.33B | 27.98B | 30.89B | 29.49B | 31.43B |
EBITDA Margin % | 34.28% | 32.1% | 34.45% | 34.1% | 32.65% | 35.98% | 34.98% | 36.28% | 33.2% | 34.11% |
EBITDA Growth % | 11.84% | -0.43% | 14.53% | -0.44% | -3.63% | 5.08% | -1.24% | 10.41% | -4.55% | 6.96% |
D&A (Non-Cash Add-back) | 3.75B | 5.64B | 6.93B | 7.01B | 7.23B | 7.39B | 6.97B | 7.49B | 7.34B | 7.39B |
EBIT | 20.53B | 18.61B | 19B | 17.65B | 16.7B | 19.36B | 19.64B | 15.83B | 17.44B | 32.17B |
Net Interest Income | -358M | -549M | -394M | 39M | -90M | -130M | 214M | 489M | 577M | 433M |
Interest Income | 368M | 385M | 611M | 357M | 111M | 53M | 490M | 1.26B | 1.33B | 1.1B |
Interest Expense | 726M | 934M | 1B | 318M | 201M | 183M | 276M | 772M | 755M | 667M |
Other Income/Expense | -1.09B | -1.22B | -3.18B | -3.64B | -3.24B | -1.76B | -1.65B | -8.35B | -5.46B | 7.46B |
Pretax Income | 19.8B▲ 0% | 17.67B▼ 10.8% | 18B▲ 1.8% | 17.33B▼ 3.7% | 16.5B▼ 4.8% | 19.18B▲ 16.3% | 19.36B▲ 0.9% | 15.06B▼ 22.2% | 16.69B▲ 10.8% | 31.5B▲ 0% |
Pretax Margin % | 27.55% | 23.12% | 22.06% | 21.12% | 19.98% | 24.36% | 24.2% | 17.69% | 18.79% | 34.19% |
Income Tax | 3.26B | 16.37B | 2.7B | 2.21B | 1.78B | 1.38B | 2.99B | 1.74B | 2.62B | 6.38B |
Effective Tax Rate % | 16.48% | 92.64% | 15.01% | 12.75% | 10.81% | 7.18% | 15.44% | 11.53% | 15.71% | 20.26% |
Net Income | 16.54B▲ 0% | 1.3B▼ 92.1% | 15.3B▲ 1076.7% | 15.12B▼ 1.2% | 14.71B▼ 2.7% | 20.88B▲ 41.9% | 17.94B▼ 14.1% | 35.15B▲ 95.9% | 14.07B▼ 60.0% | 25.12B▲ 0% |
Net Margin % | 23.01% | 1.7% | 18.75% | 18.42% | 17.82% | 26.52% | 22.43% | 41.28% | 15.84% | 27.26% |
Net Income Growth % | 7.34% | -92.14% | 1076.69% | -1.16% | -2.68% | 41.89% | -14.07% | 95.94% | -59.99% | 78.58% |
Net Income (Continuing) | 16.54B | 1.3B | 15.3B | 15.12B | 14.71B | 17.8B | 16.37B | 13.33B | 14.07B | 25.12B |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 3.08B | 1.57B | 21.83B | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | 5.93▲ 0% | 0.47▼ 92.1% | 5.61▲ 1093.6% | 5.63▲ 0.4% | 5.51▼ 2.1% | 7.81▲ 41.7% | 6.73▼ 13.8% | 13.72▲ 103.9% | 5.79▼ 57.8% | 10.34▲ 0% |
EPS Growth % | 8.21% | -92.07% | 1093.62% | 0.36% | -2.13% | 41.74% | -13.83% | 103.86% | -57.8% | 78.93% |
EPS (Basic) | 6.08 | 0.48 | 5.75 | 5.74 | 5.59 | 7.93 | 6.83 | 13.88 | 5.84 | - |
Diluted Shares Outstanding | 2.79B | 2.75B | 2.73B | 2.68B | 2.67B | 2.67B | 2.66B | 2.56B | 2.43B | 2.43B |
Basic Shares Outstanding | 2.71B | 2.68B | 2.66B | 2.63B | 2.63B | 2.63B | 2.61B | 2.53B | 2.41B | 2.43B |
Dividend Payout Ratio | 52.12% | 687.92% | 62.06% | 65.59% | 71.23% | 52.84% | 65.11% | 33.48% | 84.05% | - |
JNJ Balance Sheet
Johnson & Johnson (JNJ) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 65.03B | 43.09B | 46.03B | 45.27B | 51.24B | 60.98B | 55.29B | 53.49B | 55.89B | 54.61B |
Cash & Short-Term Investments | 41.91B | 18.3B | 19.69B | 19.29B | 25.18B | 31.61B | 22.28B | 22.93B | 24.52B | 18.56B |
Cash Only | 18.97B | 17.82B | 18.11B | 17.3B | 13.98B | 14.49B | 12.89B | 21.86B | 24.11B | 18.23B |
Short-Term Investments | 22.93B | 472M | 1.58B | 1.98B | 11.2B | 17.12B | 9.39B | 1.07B | 417M | 331M |
Accounts Receivable | 11.7B | 13.49B | 14.1B | 14.48B | 13.58B | 18.98B | 16.91B | 14.87B | 18.93B | 17.61B |
Days Sales Outstanding | 59.4 | 64.41 | 63.08 | 64.41 | 60 | 88 | 77.18 | 63.75 | 77.78 | 69.72 |
Inventory | 8.14B | 8.77B | 8.6B | 9.02B | 9.34B | 10.39B | 10.27B | 11.18B | 12.44B | 14.15B |
Days Inventory Outstanding | 136.42 | 125.76 | 115.86 | 119.48 | 119.98 | 162.01 | 152.38 | 153.7 | 165.34 | 163.36 |
Other Current Assets | 0 | 0 | 950M | 94M | 0 | -3.7B | 5.83B | 0 | 0 | 4.29B |
Total Non-Current Assets | 76.18B | 114.22B | 106.92B | 112.45B | 123.66B | 121.04B | 132.08B | 114.06B | 124.21B | 138.21B |
Property, Plant & Equipment | 15.91B | 17B | 17.04B | 17.66B | 18.77B | 18.96B | 17.98B | 19.9B | 20.52B | 53.38B |
Fixed Asset Turnover | 4.52x | 4.50x | 4.79x | 4.65x | 4.40x | 4.15x | 4.45x | 4.28x | 4.33x | 3.16x |
Goodwill | 22.8B | 31.91B | 30.45B | 33.64B | 36.39B | 35.25B | 36.05B | 36.56B | 44.2B | 48.05B |
Intangible Assets | 26.88B | 53.23B | 47.61B | 47.64B | 53.4B | 46.39B | 38.49B | 34.17B | 37.62B | 48.74B |
Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 4.43B | 4.97B | 4.18B | 5.7B | 6.56B | 10.22B | 30.62B | 14.15B | 11.41B | -18.62B |
Total Assets | 141.21B▲ 0% | 157.3B▲ 11.4% | 152.95B▼ 2.8% | 157.73B▲ 3.1% | 174.89B▲ 10.9% | 182.02B▲ 4.1% | 187.38B▲ 2.9% | 167.56B▼ 10.6% | 180.1B▲ 7.5% | 192.82B▲ 0% |
Asset Turnover | 0.51x | 0.49x | 0.53x | 0.52x | 0.47x | 0.43x | 0.43x | 0.51x | 0.49x | 0.49x |
Asset Growth % | 5.84% | 11.4% | -2.76% | 3.12% | 10.88% | 4.07% | 2.94% | -10.58% | 7.49% | 35.05% |
Total Current Liabilities | 26.29B | 30.54B | 31.23B | 35.96B | 42.49B | 45.23B | 55.8B | 46.28B | 50.32B | 50.87B |
Accounts Payable | 6.92B | 7.31B | 7.54B | 8.54B | 9.51B | 11.05B | 9.89B | 9.63B | 10.31B | 9.63B |
Days Payables Outstanding | 115.89 | 104.88 | 101.55 | 113.17 | 122.04 | 172.42 | 146.75 | 132.4 | 137 | 120.81 |
Short-Term Debt | 4.68B | 3.91B | 2.8B | 1.2B | 2.63B | 3.77B | 12.76B | 3.45B | 5.98B | 6.39B |
Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 971M | 1.85B | 818M | 2.27B | 3.48B | 3.59B | 6.64B | 3.99B | 4.13B | 3.97B |
Current Ratio | 2.47x | 1.41x | 1.47x | 1.26x | 1.21x | 1.35x | 0.99x | 1.16x | 1.11x | 1.07x |
Quick Ratio | 2.16x | 1.12x | 1.20x | 1.01x | 0.99x | 1.12x | 0.81x | 0.91x | 0.86x | 0.80x |
Cash Conversion Cycle | 79.94 | 85.28 | 77.38 | 70.72 | 57.94 | 77.58 | 82.81 | 85.04 | 106.12 | 112.26 |
Total Non-Current Liabilities | 44.5B | 66.61B | 61.97B | 62.29B | 69.12B | 62.77B | 54.77B | 52.5B | 58.29B | 62.67B |
Long-Term Debt | 22.44B | 30.68B | 27.68B | 26.49B | 32.63B | 29.98B | 26.89B | 25.88B | 30.65B | 39.41B |
Capital Lease Obligations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Deferred Tax Liabilities | 2.91B | 8.37B | 7.51B | 5.96B | 7.21B | 7.49B | 3.99B | 3.19B | 2.45B | 14.66B |
Other Non-Current Liabilities | 19.15B | 27.56B | 26.78B | 29.84B | 29.27B | 25.3B | 23.89B | 23.43B | 25.19B | 17.27B |
Total Liabilities | 70.79B | 97.14B | 93.2B | 98.26B | 111.62B | 108B | 110.57B | 98.78B | 108.61B | 113.54B |
Total Debt | 27.13B | 34.58B | 30.48B | 27.7B | 35.27B | 33.75B | 39.64B | 29.33B | 36.63B | 45.8B |
Net Debt | 8.15B | 16.76B | 12.37B | 10.39B | 21.28B | 19.26B | 26.75B | 7.47B | 12.53B | 27.56B |
Debt / Equity | 0.39x | 0.57x | 0.51x | 0.47x | 0.56x | 0.46x | 0.52x | 0.43x | 0.51x | 0.58x |
Debt / EBITDA | 1.10x | 1.41x | 1.08x | 0.99x | 1.31x | 1.19x | 1.42x | 0.95x | 1.24x | 1.46x |
Net Debt / EBITDA | 0.33x | 0.68x | 0.44x | 0.37x | 0.79x | 0.68x | 0.96x | 0.24x | 0.42x | 0.88x |
Interest Coverage | 28.78x | 20.23x | 21.07x | 65.94x | 98.17x | 114.44x | 76.13x | 30.32x | 29.34x | 48.23x |
Total Equity | 70.42B▲ 0% | 60.16B▼ 14.6% | 59.75B▼ 0.7% | 59.47B▼ 0.5% | 63.28B▲ 6.4% | 74.02B▲ 17.0% | 76.8B▲ 3.8% | 68.77B▼ 10.5% | 71.49B▲ 3.9% | 79.28B▲ 0% |
Equity Growth % | -1.03% | -14.57% | -0.68% | -0.47% | 6.4% | 16.98% | 3.76% | -10.46% | 3.95% | 38.19% |
Book Value per Share | 25.25 | 21.91 | 21.90 | 22.16 | 23.69 | 27.68 | 28.83 | 26.86 | 29.43 | 32.64 |
Total Shareholders' Equity | 70.42B | 60.16B | 59.75B | 59.47B | 63.28B | 74.02B | 76.8B | 68.77B | 71.49B | 79.28B |
Common Stock | 3.12B | 3.12B | 3.12B | 3.12B | 3.12B | 3.12B | 3.12B | 3.12B | 3.12B | 3.12B |
Retained Earnings | 110.55B | 101.79B | 106.22B | 110.66B | 113.89B | 123.06B | 128.34B | 153.84B | 155.79B | 167.28B |
Treasury Stock | -28.35B | -31.55B | -34.36B | -38.42B | -38.49B | -39.1B | -41.69B | -75.66B | -75.68B | -75.89B |
Accumulated OCI | -14.9B | -13.2B | -15.22B | -15.89B | -15.24B | -13.06B | -12.97B | -12.53B | -11.74B | -15.24B |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
JNJ Cash Flow Statement
Johnson & Johnson (JNJ) cash flow — operating, investing & free cash flow history
| Metric | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | 18.77B | 21.06B | 22.2B | 23.42B | 23.54B | 23.41B | 21.19B | 22.79B | 24.27B | 24.2B |
Operating CF Margin % | 26.11% | 27.54% | 27.21% | 28.54% | 28.5% | 29.73% | 26.5% | 26.76% | 27.32% | - |
Operating CF Growth % | -2.66% | 12.2% | 5.44% | 5.47% | 0.51% | -0.54% | -9.47% | 7.54% | 6.47% | -13.5% |
Net Income | 16.54B | 1.3B | 15.3B | 15.12B | 14.71B | 20.88B | 17.94B | 13.33B | 14.07B | 25.12B |
Depreciation & Amortization | 3.75B | 5.64B | 6.93B | 7.01B | 7.23B | 7.39B | 6.97B | 7.49B | 7.34B | 7.39B |
Stock-Based Compensation | 878M | 962M | 978M | 977M | 1B | 1.14B | 1.14B | 1.16B | 1.18B | 1.28B |
Deferred Taxes | -341M | 2.41B | -1.02B | -2.48B | -1.14B | -2.08B | -1.66B | -4.19B | -2.18B | 5.2B |
Other Non-Cash Items | -291M | -495M | 10M | -1.08B | -963M | 324M | 819M | 2.5B | 2.03B | -15.58B |
Working Capital Changes | -1.77B | 11.24B | 3M | 3.87B | 2.69B | -4.24B | -4.01B | 2.51B | 1.84B | 798M |
Change in Receivables | -1.06B | -633M | -1.19B | -289M | 774M | -2.4B | -1.29B | -624M | -406M | -1.32B |
Change in Inventory | -249M | 581M | -644M | -277M | -265M | -1.25B | -2.53B | -1.32B | -1.13B | -1.49B |
Change in Payables | -39.2B | 2.73B | -12.97B | 4.06B | 5.14B | 2.44B | 1.1B | 2.35B | 1.62B | 19M |
Cash from Investing | -4.76B | -14.87B | -3.17B | -6.19B | -20.82B | -8.68B | -12.37B | 878M | -18.6B | -20.42B |
Capital Expenditures | -3.23B | -3.28B | -3.67B | -3.5B | -3.35B | -3.65B | -4.01B | -4.54B | -4.42B | -4.61B |
CapEx % of Revenue | 4.49% | 4.29% | 4.5% | 4.26% | 4.05% | 4.64% | 5.01% | 5.33% | 4.98% | 5% |
Acquisitions | -4.51B | -35.15B | -899M | -5.81B | -7.32B | -60M | -17.65B | 0 | -15.15B | -14.46B |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | 1.14B | 1.6B | 2.74B | 3.31B | -1.2B | 417M | 65M | -3.06B | 235M | -2.15B |
Cash from Financing | -8.55B | -7.67B | -18.51B | -18.02B | -6.12B | -14.05B | -8.87B | -15.82B | -3.13B | -5.51B |
Debt Issued (Net) | 7.88B | 6.75B | -3.95B | -2.88B | 7.09B | -990M | 7.45B | -2.73B | 10.05B | 7.1B |
Equity Issued (Net) | -1000K | -1000K | -1000K | -1000K | -1000K | -1000K | -1000K | -1000K | -1000K | -2M |
Dividends Paid | -8.62B | -8.94B | -9.49B | -9.92B | -10.48B | -11.03B | -11.68B | -11.77B | -11.82B | -12.23B |
Share Repurchases | -8.98B | -6.36B | -5.87B | -6.75B | -3.22B | -3.46B | -6.04B | -5.05B | -2.43B | -2.41B |
Other Financing | 1.17B | 874M | 801M | 1.53B | 487M | 1.43B | 1.39B | -508M | 1.07B | 5.95B |
Net Change in Cash | 5.24B▲ 0% | -1.15B▼ 121.9% | 283M▲ 124.7% | -802M▼ 383.4% | -3.32B▼ 314.0% | 502M▲ 115.1% | -360M▼ 171.7% | 7.73B▲ 2247.8% | 2.25B▼ 71.0% | -1.75B▲ 0% |
Free Cash Flow | 15.54B▲ 0% | 17.78B▲ 14.4% | 18.53B▲ 4.2% | 19.92B▲ 7.5% | 20.19B▲ 1.4% | 19.76B▼ 2.1% | 17.18B▼ 13.0% | 18.25B▲ 6.2% | 19.84B▲ 8.7% | 19.06B▲ 0% |
FCF Margin % | 21.62% | 23.25% | 22.71% | 24.27% | 24.45% | 25.09% | 21.48% | 21.43% | 22.34% | 20.69% |
FCF Growth % | -1.74% | 14.39% | 4.24% | 7.48% | 1.36% | -2.13% | -13.02% | 6.19% | 8.74% | 5.57% |
FCF per Share | 5.57 | 6.48 | 6.79 | 7.42 | 7.56 | 7.39 | 6.45 | 7.13 | 8.17 | 7.85 |
FCF Conversion (FCF/Net Income) | 1.13x | 16.20x | 1.45x | 1.55x | 1.60x | 1.12x | 1.18x | 0.65x | 1.73x | 0.76x |
Interest Paid | 730M | 960M | 1.05B | 995M | 841M | 941M | 933M | 1.77B | 1.91B | 0 |
Taxes Paid | 2.84B | 3.31B | 4.57B | 4.19B | 4.62B | 4.77B | 5.22B | 8.57B | 6.71B | 0 |
JNJ Key Ratios
Johnson & Johnson (JNJ) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | 23.37% | 1.99% | 25.51% | 25.36% | 23.97% | 30.41% | 23.79% | 48.29% | 20.06% | 31.69% |
Return on Invested Capital (ROIC) | 20.11% | 18.23% | 21.31% | 22.15% | 19.17% | 17.66% | 16.01% | 19.53% | 20.73% | 18.34% |
Gross Margin | 69.69% | 66.72% | 66.79% | 66.42% | 65.58% | 70.28% | 69.25% | 68.82% | 69.07% | 68.08% |
Net Margin | 23.01% | 1.7% | 18.75% | 18.42% | 17.82% | 26.52% | 22.43% | 41.28% | 15.84% | 27.26% |
Debt / Equity | 0.39x | 0.57x | 0.51x | 0.47x | 0.56x | 0.46x | 0.52x | 0.43x | 0.51x | 0.58x |
Interest Coverage | 28.78x | 20.23x | 21.07x | 65.94x | 98.17x | 114.44x | 76.13x | 30.32x | 29.34x | 48.23x |
FCF Conversion | 1.13x | 16.20x | 1.45x | 1.55x | 1.60x | 1.12x | 1.18x | 0.65x | 1.73x | 0.76x |
Revenue Growth | 2.59% | 6.34% | 6.71% | 0.59% | 0.64% | -4.65% | 1.59% | 6.46% | 4.3% | 3.75% |
Related:JNJ Dividend History·JNJ Revenue History·JNJ Price History·JNJ P/E History·JNJ Financial Ratios·JNJ Institutional Holders
JNJ SEC Filings & Documents
Johnson & Johnson (JNJ) SEC filings — annual & quarterly reports (10-K, 10-Q)
JNJ Frequently Asked Questions
Johnson & Johnson (JNJ) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Johnson & Johnson (JNJ) reported $92.15B in revenue for fiscal year 2024. This represents a 389% increase from $18.84B in 1995.
Johnson & Johnson (JNJ) grew revenue by 4.3% over the past year. Growth has been modest.
Yes, Johnson & Johnson (JNJ) is profitable, generating $25.12B in net income for fiscal year 2024 (15.8% net margin).
Dividend & Returns
Yes, Johnson & Johnson (JNJ) pays a dividend with a yield of 2.13%. This makes it attractive for income-focused investors.
Johnson & Johnson (JNJ) has a return on equity (ROE) of 20.1%. This is excellent, indicating efficient use of shareholder capital.
Johnson & Johnson (JNJ) generated $19.06B in free cash flow for fiscal year 2024. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.